BRIDGEBIO PHARMA INC (BBIO)

Company Profile

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 392 full-time employees. The company went IPO on 2019-06-27. The firm is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The firm's pipeline of development programs ranges from early science to advanced clinical trials, which include Acoramidis (AG10), a small molecule stabilizer of transthyretin (TTR), that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloid cardiomyopathy (ATTR-CM); Low-dose infigratinib, a small molecule selective FGFR1-3 inhibitor that is in an ongoing Phase 2 clinical trial for the treatment of children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for Autosomal Dominant Hypocalcemia Type 1 (ADH1); and BBP-418, an orally administered substrate replacement product candidate for the treatment of Limb-Girdle Muscular Dystrophy type 2I, and others.

Company Info

BRIDGEBIO PHARMA INC

3160 Porter Dr., Suite 250

Palo Alto CALIFORNIA 94301

P: 16503919740

CEO: Neil Kumar

Employees: 392

Website: https://bridgebio.com/